I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
I-Mab Conference Call Information
Investors and analysts are invited to join the conference call on
Meeting URL: https://zoom.us/j/99293081819?pwd=aHJjQ0o4Uk9kUEtzeHI1dngzUGREUT09
Meeting ID: 992 9308 1819
Password: 942873
About Uliledlimab (TJD5)
Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.
About
For more information, please contact:
Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5709
Investor Inquiries:
E-mail: emilie@thepiacentegroup.com
Office line: +86 21 6039 8363
View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab-301303763.html
SOURCE